THE APEX TIMES
The Wall Street firm cited expectations for mid-to-high-teens earnings per share growth in 2027 when raising its price target on UnitedHealth.
TD Cowen has named UnitedHealth (UNH) its “2027 Best Idea,” a top-conviction stance in the firm’s coverage, and lifted its price target to $455 from $402, according to a report carried by Yahoo Finance.
The update ties TD Cowen’s call to an earnings outlook for the insurer, with the firm pointing to what it described as mid-to-high-teens growth in UnitedHealth’s earnings per share in 2027. Earnings per share, or EPS, is a key profitability metric that standardizes profit relative to shares outstanding.
The price-target increase suggests TD Cowen believes the company’s longer-term earnings power can translate into higher valuation, even as the managed-care sector continues to face pricing, utilization, and medical-cost uncertainty.
UnitedHealth is the parent of Optum, a health-services and pharmacy-management business, and UnitedHealthcare, which provides health insurance coverage. In the managed-care industry, analysts often focus on the relationship between premiums and medical costs, plus the ability of large operators to manage risk and administrative expenses.
TD Cowen’s reassessment arrives without any indication in the report that UnitedHealth itself changed guidance or announced new initiatives. The firm’s move, as described in the market note, is an analyst action rather than a company filing, earnings release, or policy update.
For investors, the “best idea” framing is typically used by brokerage teams to flag the stock they believe has the strongest risk-reward profile over a defined horizon. In this case, the horizon is 2027, and the central quantitative anchor is the projected mid-to-high-teens EPS growth.
Still, the note does not spell out the specific drivers behind the earnings forecast, such as assumptions about medical cost trends, membership growth, or Optum segment performance. Those details matter because the managed-care business can be sensitive to utilization patterns, reimbursement changes, and regulatory developments.
What to watch next is whether UnitedHealth’s subsequent company updates, such as quarterly results or investor presentations, align with TD Cowen’s longer-term EPS expectations, and whether other analysts converge on similar growth assumptions for 2027.
A reported Phase 3 win for Moderna’s personalized melanoma therapy, used alongside Merck’s Keytruda, is prompting fresh optimism that the mRNA platform can expand beyond infectious disease. Still, key details such as magnitude of benefit and full trial disclosure remain to be validated.
The company is pursuing Australian National Immunisation Program listings for its mRNA influenza vaccines after securing a March 2027 agenda spot with the PBAC, a key committee that advises public reimbursement.
The initiative, launched within Aetna, is designed to link a large share of expectant members and their newborns to coordinated maternal and infant care. CVS Health has not, in the reporting, disclosed staffing, clinical protocols, or outcome targets tied to the program.
A recent analyst upgrade focus shifted toward profitability drivers inside Medicare Advantage and the operational momentum of Optum Health, as well as what the bank characterizes as disciplined pricing.
Comments
Community guidelines. Comments may be removed for violations.
Loading comments...